What is the rationale for using buprenorphine-naloxone combination products in OUD treatment?

• A. To deter misuse by injection; naloxone has poor sublingual bioavailability but precipitates withdrawal if injected; reduces diversion.
• B. To deter misuse by mouth.
• C. To produce long-acting antagonist effects.
• D. To negate methadone's effects.

Answer: (A)

The main idea is to add a safety feature that reduces misuse by injection without compromising treatment when used as intended. Naloxone in these products has poor sublingual or oral bioavailability, so taken as prescribed, it doesn’t block buprenorphine or cause withdrawal, and the patient still gets the therapeutic relief from buprenorphine. If someone tries to inject the medication, naloxone becomes active systemically and can precipitate withdrawal, making the experience unpleasant and discouraging misuse and diversion. This combination therefore preserves the benefits of buprenorphine for opioid use disorder while reducing the incentive to misuse the product via injection.